Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.
Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.
Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.
With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”
Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Read the Full Article on Nature Medicine
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer